Sofia Dahlberg

Suggest Changes
Learn More
7013 Background: Adj chemo has been shown to improve absolute survival after resection of early stage NSCLC by 5-15%. Encouraging results with B on E4599 in advanced stage NSCLC led to trial(More)
TPS218 Background: In ECOG 4599, bevacizumab was continued as maintenance therapy following 6 cycles of PCB. This study led to the approval of PCB followed by B for first-line treatment of advanced(More)